Provided by Tiger Fintech (Singapore) Pte. Ltd.

Emergent BioSolutions

9.16
-0.2400-2.55%
Post-market: 9.390.2300+2.51%19:55 EDT
Volume:791.68K
Turnover:7.30M
Market Cap:488.70M
PE:3.62
High:9.62
Open:9.30
Low:9.04
Close:9.40
52wk High:12.73
52wk Low:4.02
Shares:53.35M
Float Shares:48.26M
Volume Ratio:0.99
T/O Rate:1.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.53
EPS(LYR):-3.5962
ROE:30.24%
ROA:5.03%
PB:0.91
PE(LYR):-2.55

Loading ...

Emergent BioSolutions Inc - to Supply Cyfendus Vaccine by March 2026

THOMSON REUTERS
·
Sep 02

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

GlobeNewswire
·
Aug 29

Emergent BioSolutions Inc. to Participate in Wells Fargo Annual Healthcare Conference

Reuters
·
Aug 27

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

GlobeNewswire
·
Aug 21

Director Kathryn C. Zoon Reports Disposal of Common Shares in Emergent BioSolutions Inc

Reuters
·
Aug 19

Donald W. DeGolyer, Director, Reports Disposal of Common Shares of Emergent BioSolutions Inc

Reuters
·
Aug 14

Aptevo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 12

Aptevo Therapeutics Reports Q2 2025 Net Loss of $6.2M, EPS at $8.40, Compared to $5.9M Loss and $1,236.96 EPS in Q2 2024

Reuters
·
Aug 11

Aptevo Therapeutics Inc expected to post a loss of $83.20 a share - Earnings Preview

Reuters
·
Aug 08

Emergent BioSolutions Files for Mixed Shelf Offering of Upto $250 Mln - Filing

THOMSON REUTERS
·
Aug 08

Emergent BioSolutions Q2 Adj. EPS $0.16 Beats $(0.72) Estimate, Sales $140.90M Beat $105.00M Estimate

Benzinga
·
Aug 07

Emergent BioSolutions Inc Outlook Q3 Total Revenues $180 Mln - $210 Mln

THOMSON REUTERS
·
Aug 07

Emergent BioSolutions Inc Outlook FY Total Revenues $765 Mln - $835 Mln

THOMSON REUTERS
·
Aug 07

Emergent BioSolutions Q2 Gross Margin 36%

THOMSON REUTERS
·
Aug 07

Emergent BioSolutions Q2 Adjusted Gross Margin 49%

THOMSON REUTERS
·
Aug 07

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

GlobeNewswire
·
Aug 07

Emergent BioSolutions Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
Aug 05

Aptevo Therapeutics Inc expected to post a loss of $83.20 a share - Earnings Preview

Reuters
·
Aug 04

Emergent BioSolutions Drops Amid Volume Spike, Last Down 5.8%

THOMSON REUTERS
·
Jul 29

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

GlobeNewswire
·
Jul 28